EMA Group Favors Naming SLS-005 an Orphan Drug for ALS

EMA Group Favors Naming SLS-005 an Orphan Drug for ALS

293623

EMA Group Favors Naming SLS-005 an Orphan Drug for ALS

A committee with the European Medicines Agency favors designating Seelos Therapeutics‘ investigational therapy SLS-005 (trehalose) an orphan drug as a potential treatment of amyotrophic lateral sclerosis (ALS), the company announced in a press release. The opinion, issued by the Committee for Orphan Medicinal Products (COMP), will now go to the European Commission (EC) for a final decision, which is expected within 30 days. The U.S. Food and Drug Administration (FDA) gave SLS-005 a similar designation for ALS late last…

You must be logged in to read/download the full post.